Mineralys Therapeutics, Inc. (MLYS)

Mineralys Therapeutics, Inc. (NASDAQ: MLYS - Get Free Report) has received an average recommendation of "Moderate Buy" from the eight ratings firms that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the

RADNOR, Pa., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced today that on February 9, 2026, the Compensation Committee of Mineralys' Board of Directors granted inducement stock option awards covering 33,504 shares and inducement restricted stock unit awards covering 25,128 shares of Mineralys common stock to two new non-executive employees.

Mineralys Therapeutics, Inc. (NASDAQ: MLYS - Get Free Report) was the recipient of some unusual options trading on Friday. Investors purchased 92,406 put options on the company. This represents an increase of approximately 3,057% compared to the average daily volume of 2,927 put options. Mineralys Therapeutics Price Performance NASDAQ: MLYS opened at $29.77 on Friday. Mineralys Therapeutics

The Dow is eyeing its best day in 10 months, as a bounce back in tech and software stocks lift Wall street

Mineralys Therapeutics, Inc. (NASDAQ: MLYS - Get Free Report) insider David Malcom Rodman sold 7,709 shares of the stock in a transaction dated Tuesday, January 13th. The shares were sold at an average price of $32.75, for a total value of $252,469.75. Following the completion of the sale, the insider directly owned 61,804 shares of the

Mineralys Therapeutics, Inc. (NASDAQ: MLYS - Get Free Report) insider David Malcom Rodman sold 6,348 shares of the stock in a transaction on Monday, January 12th. The shares were sold at an average price of $32.32, for a total value of $205,167.36. Following the completion of the sale, the insider directly owned 61,804 shares of the

Mineralys Therapeutics, Inc. (NASDAQ: MLYS - Get Free Report) CFO Adam Scott Levy sold 10,758 shares of the company's stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $32.14, for a total value of $345,762.12. Following the completion of the transaction, the chief financial officer directly

Mineralys Therapeutics, Inc. (NASDAQ: MLYS - Get Free Report) CEO Jon Congleton sold 16,236 shares of Mineralys Therapeutics stock in a transaction on Monday, January 12th. The shares were sold at an average price of $32.62, for a total transaction of $529,618.32. Following the completion of the sale, the chief executive officer owned 639,151 shares of

SG Americas Securities LLC lowered its position in Mineralys Therapeutics, Inc. (NASDAQ: MLYS) by 19.3% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 100,037 shares of the company's stock after selling 23,950 shares during the quarter. SG Americas

Mineralys Therapeutics, Inc. (NASDAQ: MLYS - Get Free Report) insider David Malcom Rodman sold 70,037 shares of the business's stock in a transaction that occurred on Friday, January 2nd. The stock was sold at an average price of $35.87, for a total transaction of $2,512,227.19. Following the completion of the sale, the insider owned 69,188 shares

RADNOR, Pa., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today issued a corporate update highlighting several recent and upcoming clinical and regulatory milestones.

Mineralys Therapeutics, Inc. (NASDAQ: MLYS - Get Free Report) has earned a consensus rating of "Moderate Buy" from the eight brokerages that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and six have given a buy recommendation to the company. The

Mineralys (MLYS) is transitioning to a pre-commercial stage, supported by robust Phase 3 data and a strengthened cash position of $593.6 million. MLYS's lorundrostat demonstrated significant efficacy in lowering systolic blood pressure, with compelling results in both real-world and specialty settings. Regulatory risk is reduced following positive pre-NDA FDA feedback and JAMA recognition, with NDA submission expected late 2025 or early 2026.

Mineralys Therapeutics leads a biotech surge, with four drug stocks up over 50% in 2025 and catalysts lining up for more upside in 2026.

MLYS, LYEL, NKTR and INSM rise more than 50% in 2025 as clinical wins, FDA approvals and M&A deals revive sector momentum heading into 2026.

New York City-based Suvretta Capital Management increased its MLYS position by 387,641 shares in the third quarter. The overall position value increased by $57.25 million from the previous period.